Pfizer Inc. $PFE Shares Sold by Berkshire Asset Management LLC PA

by · The Cerbat Gem

Berkshire Asset Management LLC PA reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 79.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 136,608 shares of the biopharmaceutical company’s stock after selling 532,631 shares during the quarter. Berkshire Asset Management LLC PA’s holdings in Pfizer were worth $3,462,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PFE. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Finally, North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. The Goldman Sachs Group upped their price target on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. TD Cowen cut their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research note on Tuesday, April 22nd. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a report on Wednesday, April 30th. Finally, Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.12.

Get Our Latest Stock Analysis on PFE

Pfizer Trading Down 0.3%

Shares of PFE stock opened at $25.07 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market cap of $142.54 billion, a P/E ratio of 13.34, a P/E/G ratio of 0.89 and a beta of 0.52. The business has a fifty day simple moving average of $24.62 and a 200-day simple moving average of $24.41. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).